Dados B3 › IGTA3 × RADL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | IGTA3 | RADL3 | year |
|---|---|---|---|
| ROE | 14.8% | 18.9% | 2025 |
| ROIC | 14.7% | 24.8% | 2025 |
| ROA | 8.1% | 5.5% | 2025 |
| Gross margin | 71.6% | 29.3% | 2025 |
| EBIT margin | 74.0% | 6.2% | 2025 |
| Net margin | 47.9% | 2.9% | 2025 |
| Net debt/EBITDA | 1.39x | 0.69x | 2025 |
| Current ratio | 2.51x | 1.46x | 2025 |
| Revenue growth (1y) | 11.6% | 13.8% | 2025 |
| Revenue growth (5y CAGR) | 12.0% | 17.1% | 2025 |
| Piotroski F-Score | 5/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | IGTA3 | RADL3 | year |
|---|---|---|---|
| P/E | 27.41x | 32.24x | 2020 × 2025 |
| P/B | 1.77x | 5.71x | 2020 × 2025 |
| EV/EBITDA | 14.65x | 9.37x | 2020 × 2025 |
| FCF yield | — | 2.5% | 2020 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:08 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it